Bibliography for: "US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics"

"US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics". Chemistry and Industry. FindArticles.com. 30 Dec, 2009. http://findarticles.com/p/articles/mi_hb5255/is_11/ai_n29442550/

Chemistry and Industry

View more issues:

Articles in June 7, 2004 issue of Chemistry and Industry

• Gent to be new chairman at GSK
  by Cath O'Driscoll
• Ibuprofen problems may affect GSK—Boots
  by Neil Eisberg
• Sussex chemistry to stay
  by Neil Eisberg
• Buncefield disaster: is the Buncefield disaster another example of how industry fails to remember lessons from the past?
  by Emma Dorey
• BPA safety
  by Jasmin Bird
• Dissolving wood with ionic liquids
  by Andrew Turley
• Permit glut damages emission trading
  by Patrick Walter
• Seeding research into tropical GM crops
• Fido finds the feelgood factor
  by John House
• Reinventing drug development
  by Chris Ashton
• Understanding life after death
  by Geoffrey Davies
• Chemistry, Energy and the Environment
  by Geoff Dolbear
• Polymer Latices, vols. 1-3, 2nd ed
  by Henry Warson
• Treatment Innovation for the Next Century: Innovation 2000
  by Nigel Stevens
• The Beilstein System: Strategies for Effective Searching
  by Declan Kennedy
• Holmes, Chemistry and the Royal Institution
  by Gordon Rutter
• Advanced materials
  by Arno Kraft
• Analytical chemistry
  by Tom McGreedy
• Realising the potential of plants
  by Ian Bartle
• Animal welfare centre will not stop menace
  by Cath O'Driscoll
• Monsanto v Schmeiser
• Stem cells
• Beagle bungle.
• Moratorium over: so what?
  by Marina Murphy
• Celltech: wake-up call to save UK biotech
  by Cath O'Driscoll
• Kirin breeds cow with BSE barrier
  by Marina Murphy
• CJD timebomb
• 21 year-old sperm
• Biotech pipeline boost
• Stockholm convention: 12 POPs outlawed
  by Cath O'Driscoll
• Breast cancer gene
• Chiron's Powderject forms new PowderMed
  by Cath O'Driscoll
• Sars vaccine on road to success
• Platinum Equity eyes Dystar deal
• Harris pays penalty
• Yara welcomes flotation
• Purchases approved
• Blight-resistant crops
  by Cath O'Driscoll
• Starvation activates long-life gene
  by Cath O'Driscoll
• Pig cloning for human transplant
  by Marina Murphy
• Self-healing reactor materials
  by Cath O'Driscoll
• Highly efficient alumina production
  by Robert Winder
• The day after tomorrow: can a blockbuster disaster movie change the way we think? Marina Murphy reports on the realities of climate change
  by Marina Murphy
• Diary 2004
• REACH
  by Melvyn Whyte
• NGOs' accountability?
  by E. Clarke
• Micro hearing aid
• X-ray calibration
• Shaped ice-cream
• Insect repellent
• Tea with a facelift?
• Communication and reputation
• An end to animal testing: Wendy Higgins, campaigns director at the British Union for the Abolition of Vivisection, www.buav.org, discusses why the chemicals industry must do more to end animal testing
  by Wendy Higgins
• Farming food & health: David Atkinson asks whether organic food is better for us than conventionally farmed food
  by David Atkinson
• Electronic data capture: Steve Powell wonders whether the pharmaceuticals industry is capable of delivering on its promised pipeline
  by Steve Powell
• Optimising pesticide use
  by Ray Bates
• Nanoparticles: from theory to application
  by Michael Gross
• Advances materials
  by Arno Kraft
• Analytical chemistry
  by Tom McCreedy
• Werner Cautreels, currently global vice president, R&D, of Solvay's pharmaceutical sector
• Axel Westerhaus, currently serving as head of polyethers in the Bayer MaterialScience sub-group, assumed responsibility Bayer Chemicals' fine chemicals business unit LANXESS on 1 June
• Medco Health Solutions
• Solvitol
• Abingworth Management
• Oxagen
• Secret filings
• Why are we waiting?
• Reactor cracking up
• Viagra and blindness
• Human error blamed for deaths
  by Neil Eisberg
• Republican revolt could see off veto
  by Patrick Walter
• US GM corn shipment impounded in Ireland
• Miniscule molecular transistor
  by Marina Murphy
• Cashless deal signed
• Speciality merger
• Vitamin C in Scotland
• Akzo Swedish investment
• Solvay expands capacity
• Warnings: falling on deaf ears
  by Emma Dorey
• Justification need for animal tests
  by Marina Muprhy

• 1
• 2
• 3
• 4
• 5
• 6